Silver Book Fact

Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.

Ettinger B, Black D, Mitlak B, et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999; 282(7): 637-45. http://jama.ama-assn.org/cgi/content/abstract/282/7/637?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Reduction+of+Vertebral+Fracture+Risk+in+Postmenopausal+Women+with+Osteoporosis+Treated+with+Raloxifene&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Reference

Title
Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial
Publication
JAMA
Publication Date
1999
Authors
Ettinger B, Black D, Mitlak B, et al
Volume & Issue
Volume 282, Issue 7
Pages
637-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…  
  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…